Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Francisco, California 94143


Purpose:

The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and Treg differentiation of naïve T cells.


Criteria:

Inclusion Criteria: - Relapsing-remitting (RR) MS patients (McDonald criteria) - Ages 18-55 - Males and females - EDSS score ≤5 - No prior treatment with Copaxone - Prior treatment with corticosteroids or interferon-beta (-1a or -1b) is acceptable, provided there is a washout period of at least one month Exclusion Criteria: - Treatment with Tysabri, Novantrone or cyclophosphamide - Treatment with other immunomodulatory therapies (e.g. imuran, mycophenolate or methotrexate) - Primary-progressive (PP) and secondary-progressive (SP) multiple sclerosis - Pregnancy


NCT ID:

NCT00819195


Primary Contact:

Principal Investigator
Scott S. Zamvil, M.D. Ph.D.
UCSF Department of Neurology


Backup Contact:

N/A


Location Contact:

San Francisco, California 94143
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.